Synergistic effects of glycated chitosan with high-intensity focused ultrasound on suppression of metastases in a syngeneic breast tumor model

Cell Death and Disease

Volumn 5, Issue 4, 2014, Pages

  Chen, Y L ^a   Wang, C Y ^b   Yang, F Y ^a   Wang, B S ^a   Chen, J Y ^c   Lin, L T ^a   Leu, J D ^d   Chiu, S J ^e   Chen, F D ^f   Lee, Y J ^a,d   Chen, W R ^g  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b CHENG HSIN GENERAL HOSPITAL   (Taiwan)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TAIPEI CITY HOSPITAL   (Taiwan)

^e TZU CHI UNIVERSITY   (Taiwan)

^f CHINESE CULTURE UNIVERSITY   (Taiwan)

^g UNIVERSITY OF CENTRAL OKLAHOMA   (United States)

Author keywords

Breast cancer; Epithelial mesenchymal transition; High intensity focused ultrasound; Immunoadjuvant; Lung metastasis

Indexed keywords

CHITOSAN DERIVATIVE; GLYCOSYLATED CHITOSAN; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR TWIST; UNCLASSIFIED DRUG; UVOMORULIN; CHITOSAN; GLYCATED CHITOSAN; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HIGH INTENSITY FOCUSED ULTRASOUND; IMMUNOSTIMULATION; MACROPHAGE ACTIVATION; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTO ONCOGENE; TUMOR INVASION; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CELL DEATH; CELL MOTION; DIAGNOSTIC IMAGING; DISEASE MODEL; DRUG EFFECTS; GENETIC TRANSFECTION; HUMAN; MACROPHAGE; METABOLISM; PATHOLOGY; REPORTER GENE; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; CELL MOVEMENT; CHITOSAN; DIAGNOSTIC IMAGING; DISEASE MODELS, ANIMAL; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENES, REPORTER; HIGH-INTENSITY FOCUSED ULTRASOUND ABLATION; HUMANS; MACROPHAGES; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84900992983     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.159     Document Type: Article

References (43)

1. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 563-572.
2. Hainaut P, Plymoth A. Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy. Curr Opin Oncol 2013; 25: 50-51.
3. Wells A, Grahovac J, Wheeler S, Ma B, Lauffenburger D. Targeting tumor cell motility as a strategy against invasion and metastasis. Trends Pharmacol Sci 2013; 34: 283-289.
4. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012; 12: 237-251.
5. Azuma I, Seya T. Development of immunoadjuvants for immunotherapy of cancer. Int Immunopharmacol 2001; 1: 1249-1259.
6. Chen WR, Singhal AK, Liu H, Nordquist RE. Antitumor immunity induced by laser immunotherapy and its adoptive transfer. Cancer Res 2001; 61: 459-461.
7. Ma X, Pan H, Yi J. Combination sonodynamic therapy with immunoadjuvant may be a promising new modality for cancer treatment. Med Hypothes 2009; 72: 418-420.
8. Chen WR, Liu H, Ritchey JW, Bartels KE, Lucroy MD, Nordquist RE. Effect of different components of laser immunotherapy in treatment of metastatic tumors in rats. Cancer Res 2002; 62: 4295-4299.
9. Kafetzopoulos D, Martinou A, Bouriotis V. Bioconversion of chitin to chitosan: purification and characterization of chitin deacetylase from Mucor rouxii. Proc Natl Acad Sci USA 1993; 90: 2564-2568.
10. Chen WR, Carubelli R, Liu H, Nordquist RE. Laser immunotherapy: a novel treatment modality for metastatic tumors. Mol Biotechnol 2003; 25: 37-44.
11. Song S, Zhou F, Nordquist RE, Carubelli R, Liu H, Chen WR. Glycated chitosan as a new non-toxic immunological stimulant. Immunopharmacol Immunotoxicol 2009; 31: 202-208.
12. Zhou F, Song S, Chen WR, Xing D. Immunostimulatory properties of glycated chitosan. J X-ray Sci Technol 2011; 19: 285-292.
13. Chen WR, Korbelik M, Bartels KE, Liu H, Sun J, Nordquist RE. Enhancement of laser cancer treatment by a chitosan-derived immunoadjuvant. Photochem Photobiol 2005; 81: 190-195.
14. Nordquist RE, Bishop SL, Ferguson H, Vaughan MB, Jose J, Kastl K et al. Immunohistochemical analysis of immune response in breast cancer and melanoma patients after laser immunotherapy. Proc. SPIE 7900, Biophotonics and Immune Responses VI, 790007; 23 February 2011, pp 790007-790010; doi:10.1117/12.874875.
15. Li X, Min M, Du N, Gu Y, Hode T, Naylor M et al. Chitin, chitosan, and glycated chitosan regulate immune responses: the novel adjuvants for cancer vaccine. Clin Dev Immunol 2013; 2013: 387023.
16. Zhou F, Wu S, Song S, Chen WR, Resasco DE, Xing D. Antitumor immunologically modified carbon nanotubes for photothermal therapy. Biomaterials 2012; 33: 3235-3242.
17. Li X, Ferrel GL, Guerra MC, Hode T, Lunn JA, Adalsteinsson O et al. Preliminary safety and efficacy results of laser immunotherapy for the treatment of metastatic breast cancer patients. Photochem Photobiol Sci 2011; 10: 817-821.
18. Hung BP. The effect of high intensity focused ultrasound ablation of human breast cancer. Surgery 2010; 147: 466-467.
19. Wu F, ter Haar G, Chen WR. High-intensity focused ultrasound ablation of breast cancer. Expert Rev Anticancer Ther 2007; 7: 823-831.
20. Haen SP, Pereira PL, Salih HR, Rammensee HG, Gouttefangeas C. More than just tumor destruction: immunomodulation by thermal ablation of cancer. Clin Dev Immunol 2011; 2011: 160250.
21. Xu J, Bigelow TA, Riesberg GM. Impact of preconditioning pulse on lesion formation during high-intensity focused ultrasound histotripsy. Ultrasound Med Biol 2012; 38: 1918-1929.
22. Hu Z, Yang XY, Liu Y, Morse MA, Lyerly HK, Clay TM et al. Release of endogenous danger signals from HIFU-treated tumor cells and their stimulatory effects on APCs. Biochem Biophys Res Commun 2005; 335: 124-131.
23. Zavadil J, Bottinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005; 24: 5764-5774.
24. Fendrich V, Waldmann J, Feldmann G, Schlosser K, König A, Ramaswamy A et al. Unique expression pattern of the EMT markers Snail, Twist and E-cadherin in benign and malignant parathyroid neoplasia. Eur J Endocrinol/Eur Fed Endocr Soc 2009; 160: 695-703.
25. Montserrat N, Gallardo A, Escuin D, Catasus L, Prat J, Gutié rrez-Avignó FJ et al. Repression of E-cadherin by SNAIL, ZEB1, and TWIST in invasive ductal carcinomas of the breast: a cooperative effort? Hum Pathol 2011; 42: 103-110.
26. Chen WR, Adams RL, Carubelli R, Nordquist RE. Laser-photosensitizer assisted immunotherapy: a novel modality for cancer treatment. Cancer Lett 1997; 115: 25-30.
27. Chen WR, Zhu WG, Dynlacht JR, Liu H, Nordquist RE. Long-term tumor resistance induced by laser photo-immunotherapy. Int J Cancer J 1999; 81: 808-812.
28. Chen WR, Jeong SW, Lucroy MD, Wolf RF, Howard EW, Liu H et al. Induced antitumor immunity against DMBA-4 metastatic mammary tumors in rats using laser immunotherapy. Int J Cancer 2003; 107: 1053-1057.
29. Liu HL, Hsieh HY, Lu LA, Kang CW, Wu MF, Lin CY. Low-pressure pulsed focused ultrasound withmicrobubbles promotes an anticancer immunological response. J TranslMed 2012; 10: 221.
30. Lu P, Zhu XQ, Xu ZL, Zhou Q, Zhang J, Wu F. Increased infiltration of activated tumorinfiltrating lymphocytes after high intensity focused ultrasound ablation of human breast cancer. Surgery 2009; 145: 286-293.
31. Wu F, Zhou L, Chen WR. Host antitumour immune responses to HIFU ablation. Int J Hyperthermia 2007; 23: 165-171.
32. Yang FY, Lin GL, Horng SC, Chen RC. Prenatal exposure to diagnostic ultrasound impacts blood-brain barrier permeability in rats. Ultrasound Med Biol 2012; 38: 1051-1057.
33. Khokhlova TD, Hwang JH. HIFU for palliative treatment of pancreatic cancer. J Gastrointest Oncol 2011; 2: 175-184.
34. Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004; 118: 277-279.
35. Tran DD, Corsa CA, Biswas H, Aft RL, Longmore GD. Temporal and spatial cooperation of Snail1 and Twist1 during epithelial-mesenchymal transition predicts for human breast cancer recurrence. Mol Cancer Res 2011; 9: 1644-1657.
36. Iacobelli S, Ranelletti FO, Longo P, Riccardi R, Mastrangelo R. Discrepancies between in vivo and in vitro effects of glucorticoids in myelomonocytic leukemic cells with steroid receptors. Cancer Res 1978; 38: 4257-4262.
37. Schug M, Stober R, Heise T, Mielke H, Gundert-Remy U, Godoy P et al. Pharmacokinetics explain in vivo/in vitro discrepancies of carcinogen-induced gene expression alterations in rat liver and cultivated hepatocytes. Arch Toxicol 2013; 87: 337-345.
38. Schurgers E, Kelchtermans H, Mitera T, Geboes L, Matthys P. Discrepancy between the in vitro and in vivo effects of murine mesenchymal stem cells on T-cell proliferation and collagen-induced arthritis. Arthritis Res Ther 2010; 12: R31.
39. Bove K, Lincoln DW, Tsan MF. Effect of resveratrol on growth of 4T1 breast cancer cells in vitro and in vivo. Biochem Biophys Res Commun 2002; 291: 1001-1005.
40. Chavez KJ, Garimella SV, Lipkowitz S. Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis 2010; 32: 35-48.
41. Chen YL, Wang SY, Liu RS, Wang HE, Chen JC, Chiou SH et al. Remnant living cells that escape cell loss in late-stage tumors exhibit cancer stem cell-like characteristics. Cell Death Dis 2012; 3: e399.
42. Yang FY, Wang HE, Lin GL, Teng MC, Lin HH, Wong TT et al. Micro-SPECT/CT-based pharmacokinetic analysis of 99mTc- diethylenetriaminepentaacetic acid in rats with blood- brain barrier disruption induced by focused ultrasound. J Nucl Med 2011; 52: 478-484.
43. Yang FY, Wang HE, Liu RS, Teng MC, Li JJ, Lu M et al. Pharmacokinetic analysis of 111 in-labeled liposomal Doxorubicin in murine glioblastoma after blood-brain barrier disruption by focused ultrasound. PLoS One 2012; 7: e45468.